Reporting owner · CIK 0001351779

Kidron Nadav

Visual SEC Form 4 history across 1 companies, 17 transactions and 5 filings.

PRESPresident and CEOORAMED PHARMACEUTICALS INC.
Open-market mix
Filings5Form 4 records
Buying$00 purchases
Selling$00 sales
Net value$0Buys minus sells
Companies13 securities
Most recentSep 24, 2026return

Latest insider transactions

Form 4 filings from available history. Click any column to sort; click it again to flip the order.

Kidron Nadav transactions
IDTickerInsiderRoleTypeSharesValueCodeFiledTrans date
#229816ORMPKidron Nadav
PRES
return107k—D09/2509/24
#229815ORMPKidron Nadav
PRES
return150k—D09/2509/24
#229814ORMPKidron Nadav
PRES
return97.0k—D09/2509/24
#229813ORMPKidron Nadav
PRES
return49.0k—D09/2509/24
#229812ORMPKidron Nadav
PRES
return190k—D09/2509/24
#229811ORMPKidron Nadav
PRES
return196k—D09/2509/24
#229810ORMPKidron Nadav
PRES
grant368k—A09/2509/24
#229809ORMPKidron Nadav
PRES
grant349k—A09/2509/24
#215772ORMPKidron Nadav
PRES
exercise109k$0M01/2901/22
#215771ORMPKidron Nadav
PRES
exercise109k$0M01/2901/22

Latest Form 4 facts

Quick context from source filings

Latest transaction

No latest transaction fact is available.

Latest buy

No open-market insider purchase is available.

Latest sale

No open-market insider sale is available.

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

9 observations · Jan 2, 2025 – Sep 24, 2026. Window ends at the latest available report, not today.

Selected observation · Sep 24, 20264,140,505 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Jan 2, 20252,259,598Jan 6, 2025View transaction
Feb 11, 20252,400,598Feb 11, 2025View transaction
Feb 11, 20252,586,598Feb 11, 2025View transaction
Feb 11, 20252,686,598Feb 11, 2025View transaction
Dec 31, 20252,919,238Jan 5, 2026View transaction
Dec 31, 20253,246,238Jan 5, 2026View transaction
Jan 22, 20263,355,238Jan 29, 2026View transaction
Sep 24, 20263,771,740Sep 25, 2026View transaction
Sep 24, 20264,140,505Sep 25, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
No open-market purchases or sales in this history.

Net value flow

Buys minus sells

Jan 25
$0
Feb 25
$0
Dec 25
$0
Jan 26
$0
Sep 26
$0

Transaction texture

Ownership and ticket size

Average P/S size—
Median P/S size—
Direct17
Indirect0
Sep 24, 2026return

Associated companies

Visual map of known reporting history

Kidron Nadav Insider Activity FAQ

SEC Form 4 context

Who is Kidron Nadav?

Kidron Nadav is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001351779.

Which companies has Kidron Nadav reported transactions for?

ORAMED PHARMACEUTICALS INC.

When was Kidron Nadav's latest insider buy?

No open-market insider purchase is available for this period.

When was Kidron Nadav's latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.